Novartis’ VANRAFIA Approval Spurs Competition in IgA Nephropathy Treatment Market
Travere Therapeutics Inc. is well-positioned to capitalize on the evolving IgA nephropathy treatment market, driven by the recent FDA approval of VANRAFIA and growing demand for specialized therapies in rare diseases.
2 minutes to read